Novo Nordisk A/S

NYSE:NVO

Drug Manufacturers - General

Healthcare
$39.43 -1.09%

-$0.48 today

Market cap
$173.82B
Beta
0.35
P/E (TTM)
10.2
EPS (TTM)
$27.45
Dividend yield
4.18%
52W Low $35.12High $74.38

Volume 16.12M

Average 16.05M

NVO Dividends Paid

Cash distributed to shareholders as dividends.

Novo Nordisk A/SNYSE: NVO

Dividends Paid · Q2 FY2026 · quarter ended Jun 2026

Dividends paid outflow shrinks to DKK 0

Q2 FY2026 dividends paid was DKK 0, compared with DKK 174M a year earlier. Trailing-twelve-month dividends paid was -DKK 51.98B. Over 3 fiscal years it compounded at +26.9% a year.

Context

  • Dividends paid amounted to 16.7% of revenue in FY2025, up 1.5 pp from a year earlier.
  • Dividends paid grew in size in 3 of the last 3 fiscal years.
  • FY2025 was the largest annual figure in the 4 fiscal years shown.

What to watch

Whether quarterly dividends paid holds near DKK 0 or moves back toward the trailing-twelve-month quarterly average of -DKK 12.99B.

Sources:Cash FlowText generated from reported figures; not investment advice.

Latest quarterJun 2026
DKK 0+100.0% QoQ
Last fiscal yearDec 2025
-DKK 51.76B+17.3% YoY
LTMJun 2026
-DKK 51.98B+2.5% YoY
Dividends Paid past and forecast growth by horizon
Horizon Past Forecast Difference
Quarter-100.0%——
1 year+17.3%——
3-year CAGR+26.9%——
5-year CAGR——
10-year CAGR——

Dividends Paid history

DKK · from the cash flow

Latest · FY2025
(51.76B) DKK
Year-over-year change
-17.3%

Dividends Paid vs competitors

How NVO compares with its peers on the latest reported figures

  • Peers report in different currencies, so dividends paid is compared through growth and share of revenue rather than absolute size.
  • Its year-over-year change of +2.5% is the 7th highest of 9, against a peer median of +4.8%.
  • Dividends paid amounts to 15.8% of revenue for NVO, versus a peer median of 12.5%.
NVO Competitors
Dividends Paid for NVO and competitors
Company Period LTM YoY 3-year CAGR% of revenue
NVONovo Nordisk A/SLTM Jun 2026DKK 51.98B DKK+2.5%+26.9%15.8%
JNJJohnson & JohnsonLTM Sep 2026$12.72B USD+3.9%+2.0%12.8%
ABBVAbbVie Inc.LTM Jun 2026$11.98B USD+5.6%+5.1%18.6%
PFEPfizer Inc.LTM Jun 2026$9.79B USD+1.5%+2.8%15.4%
MRKMerck & Co., Inc.LTM Jun 2026$8.3B USD+3.3%+5.3%12.5%
LLYEli Lilly and CompanyLTM Jun 2026$5.78B USD+15.0%+15.0%7.3%
SNYSanofiLTM Jun 2026€5.74B EUR—+8.9%11.7%
AMGNAmgen Inc.LTM Jun 2026$5.29B USD+6.3%+6.9%13.9%
AZNAstraZeneca PLCLTM Sep 2026$4.93B USD-0.7%+4.4%7.9%
GSKGSK plcLTM Jun 2026£2.91B GBP+16.6%-16.3%8.8%
Peer median (excluding NVO) —+4.8%+5.1%12.5%

Competitors are the stored peer set for NVO. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.

Cash Flow Statement

DKK
Metric
FY2021
Dec 2021
FY2022
Dec 2022
FY2023
Dec 2023
FY2024
Dec 2024
FY2025
Dec 2025
Net Income47.76B55.53B83.68B100.99B102.43B
Depreciation & Amortization6.03B7.36B9.41B19.11B21.98B
Deferred Income Tax11.32B13.54B20.99B26.2B28.11B
Stock-Based Compensation1.04B1.54B2.15B2.29B0
Change in Working Capital(8.66B)(5.54B)(12.25B)2.59B3.74B
Accounts Receivables(12.91B)(10.82B)(14.21B)(14.31B)0
Inventory(1.09B)(4.77B)(7.42B)(9.04B)0
Accounts Payables3.15B6.72B10.02B3.24B0
Other Working Capital2.19B3.34B(631M)22.7B3.74B
Other Non-Cash Items(2.49B)6.46B4.92B(30.21B)(37.16B)
Operating Cash Flow55B78.89B108.91B120.97B119.1B
Capital Expenditures(7.39B)(14.75B)(38.9B)(51.31B)(90.11B)
Acquisitions (Net)(18.28B)(7.08B)0(82.16B)1B
Purchases of Investments(7.11B)(9.74B)(13.29B)(19.81B)(723M)
Sales of Investments1.17B6.65B8.29B24.39B10.67B
Other Investing Activities4M(2.61B)(13.09B)(4.15B)(29.97B)
Investing Cash Flow(31.61B)(24.92B)(43.89B)(128.9B)(79.16B)
Debt Repayment15.47B(2.41B)(1.47B)73.06B24.74B
Common Stock Issued00000
Common Stock Repurchased(19.45B)(24.09B)(29.92B)(20.18B)(1.39B)
Dividends Paid(21.52B)(25.3B)(31.77B)(44.14B)(51.76B)
Other Financing Activities00000
Financing Cash Flow(25.49B)(51.8B)(63.16B)8.74B(28.41B)
Effect of Forex Changes591M(238M)(119M)455M(727M)
Net Change in Cash(1.51B)1.93B1.74B1.26B10.81B
Free Cash Flow47.62B64.13B70.01B69.66B28.99B

Novo Nordisk A/S

NYSE:NVO

Intrinsic Alpha fair value

Locked

Current Price

$39.43

Margin of safety hidden

Unlock the intrinsic value to see where the current price sits on the valuation runway.

Valuation runway

Locked

Get the intrinsic value and margin of safety with a free account.